XLRN Acceleron Pharma Inc.

+0.35  (+1%)
Previous Close 42.9
Open 42.75
Price To Book 4.46
Market Cap 2278658255
Shares 52,685,740
Volume 269,312
Short Ratio
Av. Daily Volume 301,984

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 1H 2020.
Sotatercept - PULSAR
Pulmonary arterial hypertension (PAH)
Phase 3 trial initiated - noted October 30, 2018.
Luspatercept - COMMANDS
First-line, lower-risk Myelodysplastic syndromes (MDS)
Phase 2 data 2H 2019.
Phase 2 data due 1Q 2020.
Charcot-Marie-Tooth disease (CMT)
BLA filing announced April 5, 2019.
Myelodysplastic syndromes (MDS) cancer
Phase 2 updated data at ASH 2016.
Low or intermediate-risk MDS patients who are erythropoiesis-stimulating agent (ESA) naïve or ring sideroblast negative (RS-)
Phase 2 Part 2 data due 2H 2019.
Facioscapulohumeral muscular dystrophy
Phase 2 data released June 12, 2017 - primary endpoint not met.
Dalantercept - DART Study
Renal Cell Carcinoma (RCC) - cancer
Phase 2 updated data at ASCO June 2018. 55% achieved a clinically meaningful erythroid improvement.
Luspatercept Extension Study - PACE-MDS
Myelodysplastic Syndromes
Announced April 4, 2019 intention to discontinue development.
Healthy volunteers
Phase 2 data due 2020.
Luspatercept - BEYOND
Non-transfusion-dependent beta-thalassemia

Latest News

  1. Edited Transcript of XLRN earnings conference call or presentation 9-May-19 9:00pm GMT
  2. Acceleron to Present at the UBS Global Healthcare Conference
  3. Acceleron Pharma (XLRN) Reports Q1 Loss, Misses Revenue Estimates
  4. Acceleron: 1Q Earnings Snapshot
  5. Acceleron Reports First Quarter 2019 Operating and Financial Results
  6. Drug/Biotech Stock Q1 Earnings on May 9: IONS, XLRN & More
  7. 5 Must-Buy Stocks Ahead of Q1 Earnings Amid Market Volatility
  8. Will Life Sciences Sales Boost Bio-Rad's (BIO) Q1 Earnings?
  9. Telenav (TNAV) to Report Q3 Earnings: What's in the Offing?
  10. Can Epidolex Drive GW Pharmaceuticals' (GWPH) Q2 Earnings?
  11. Acceleron to Webcast First Quarter 2019 Operating and Financial Results on May 9, 2019
  12. Here’s What Hedge Funds Think About Acceleron Pharma Inc (XLRN)
  13. Celgene (CELG) Q1 Earnings Beat Estimates on Revlimid Sales
  14. Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Marketing Authorization Application to the European Medicines Agency (EMA) for MDS and Beta-Thalassemia
  15. If You Had Bought Acceleron Pharma (NASDAQ:XLRN) Shares Three Years Ago You'd Have Made 36%
  16. Edited Transcript of XLRN earnings conference call or presentation 27-Feb-19 10:00pm GMT
  17. Celgene & Acceleron Submit BLA for Luspatercept to the FDA
  18. Acceleron Announces Departure of Chief Medical Officer